Here are five things to know:
1. The acquisition will add SpineSelect’s unique minimally invasive transforaminal lumbar interbody fusion system to Amendia’s product portfolios.
2. SpineSelect’s MITLIF system includes the Marquise MIS Channel System and Turbo MIS TLIF System, covered by 20 patents. The technology is designed for less invasive lumbar fusion procedures to improve patient outcomes.
3. The Turbo MIS system is an interbody device with a standalone FDA clearance. The Marquise MIS system is designed to limit muscle damage while providing surgeons with the adequate access to perform complex procedures.
4. Amendia was founded in 2008 to focus on disruptive technologies for medical devices. SpineSelect was launched just a year later, in 2009, by a spine surgeon with more than 40 years of experience in the field.
5. Amendia is headquartered in Marietta, Ga., and has a vertically-integrated strategy to focus on improving surgical outcomes and patients with spinal disorders.
“We look forward to building relationships with SpineSelect’s current customers and distribution groups, while expanding our product portfolio with novel technologies,” said Amendia CEO Jeff Smith.
More articles on orthopedic devices:
8 new device launches & releases
InVivo Therapeutics secures expanded patent for Neuro-Spinal Scaffold
Medtronic facing product liability lawsuit over Infuse once more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
